Both the studies in preclinical tumor models (including our MeVa2.1.dOVA melanoma model) and in patients with advanced melanoma showed an increase in the expression of the IFN-γ signature genes and the CD8/Treg ratio with domatinostat treatment (Fig. 1 D; Bretz et al., 2019; Hassel et al., 2021). This evidence concerns the gene IFNG and melanoma.